Pastor, Jose C.
Pastor-Idoate, Salvador http://orcid.org/0000-0002-6463-4227
López-Paniagua, Marina
Para, Marta
Blazquez, Francisco
Murgui, Esther
García, Verónica
Coco-Martín, Rosa M.
Funding for this research was provided by:
Strategic Action in Health of the Institute of Health Carlos III (PIC18/00018)
Department of Regional Health of the Castilla y Léon Government (GRS 1928/A/19)
Consejería de Educación, Junta de Castilla y León (Grant VA077P17)
Article History
Received: 28 February 2023
Accepted: 14 September 2023
First Online: 21 September 2023
Declarations
:
: The Clinical Research Ethics Committee of the Valladolid East Health Area and the Spanish Agency for Medicine and Medical Devices (AEMPS) approved the study protocol, which followed European laws and the Declaration of Helsinki with its subsequent amendments. project title; ESTUDIO FASE I DE LA SEGURIDAD DE LAS CÉLULAS MADRE MESENQUIMALES MSV® EN INYECCIÓN INTRAVÍTREA PARA EL TRATAMIENTO DE PACIENTES CON NEUROPATÍA ÓPTICA ISQUÉMICA ANTERIOR NO ARTERÍTICA AGUDA. CÓDIGO PROMOTOR: IOBA-01-2016 Nº EUDRA: 2016-001032-35, approval number; CASVE 16-261, date of approval; 01-06-2016).
: Not applicable.
: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Presented in part at the VII International Congress of Research in Retina and Vision, June 24–26, 2021, Murcia, Spain, and the LIII Congress of Andalusian Society of Ophthalmology, June 24, 2021, Sevilla, Spain.